NEWS & EVENTS
Michigan Medicine Laboratories a leading full-service reference laboratory will participate in the upcoming 103rd Annual Texas Society Pathology Conference in Austin, Texas from February 2-4, 2024.
It is with deep sadness that we announce the death of David O. Ferguson, MD, PhD, Associate Professor of Pathology. David passed away suddenly at the age of 57 on Saturday, January 6, 2024. He is survived by his wife, Dr. JoAnn Sekiguchi (Associate Professor and Associate Chair of Human Genetics, University of Michigan Medical School), their daughter, Brianna, and his brother, Peter Ferguson of HendersoFerguson_David_2011 sq 500.jpgn, NV.
Dr. Jonathan McHugh, Clinical Professor in the Department of Pathology, was appointed A. James French Professor of Surgical Pathology by approval of the Regents of the University of Michigan in May 2021. Celebration of his professorship was delayed due to COVID-19 and his official investiture ceremony was held on January 10, 2024. This professorship was created to build on the high value our department places on our clinical mission by recognizing a senior faculty member who has made significant contributions to our department’s clinical service, research, and training programs. It comes with an endowment to support programs in surgical pathology.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.